Cash Flow Valuation

Showing 1919 articles
Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

Sea Limited's Stock Plunge: A Buying Opportunity or a Value Trap?

Sea Limited's shares have tumbled over 11% year-to-date, sparking debate among investors. While a discounted cash flow model suggests the stock is deeply undervalued, its lofty P/E ratio tells a more cautious tale. We examine the conflicting signals and what they mean for the Southeast Asian tech giant's future.